Review
Nature Reviews Drug Discovery 6, 821-833 (October 2007) | doi:10.1038/nrd2359
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
David R. Clemmons1 About the author
Abstract
Insulin-like growth factor 1 (IGF1) is a polypeptide hormone that has a high degree of structural similarity to human proinsulin. Owing to its ubiquitous nature and its role in promoting cell growth, strategies to inhibit IGF1 actions are being pursued as potential adjunctive measures for treating diseases such as short stature, atherosclerosis and diabetes. In addition, most tumour cell types possess IGF1 receptors and conditions in the tumour microenvironment, such as hypoxia, can lead to enhanced responsiveness to IGF1. Therefore, inhibiting IGF1 action has been proposed as a specific mechanism for potentiating the effects of existing anticancer therapies or for directly inhibiting tumour cell growth.
- View At a Glance
Author affiliations
-
Division of Endocrinology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7170, USA.
Email: endo@med.unc.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Developmental biology: Autocrine control of growth?Nature News and Views (18 Oct 1984)
Cardiac performance: Growth hormone enters the raceNature Medicine News and Views (01 Jan 1996)
RESEARCH
BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responsesThe EMBO Journal Article (11 Jul 2007)
See all 67 matches for Research
